3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
3
Thoracic
1
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia, B-Cell
2
Neoplasms
1
Motor Activity
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma
1
Leukemia
1
Dementia
1
Cognitive Dysfunction
1
Alzheimer Disease
1
Interventions
Cyclophosphamide
35
Rituximab
33
venetoclax
24
ibrutinib
14
Vincristine
14
Prednisone
14
Doxorubicin
14
Gemcitabine
13
pembrolizumab
12
fludarabine
12
Bendamustine Hydrochloride
11
Etoposide
10
obinutuzumab
9
Filgrastim
9
Dexamethasone
9
Bortezomib
9
fludarabine phosphate
8
Mycophenolic Acid
8
Drug Therapy
8
ofatumumab
7
Whole-Body Irradiation
7
Sirolimus
7
Peripheral Blood Stem Cell Transplantation
7
Methotrexate
7
Busulfan
7
Therapeutics
6
Radiotherapy
6
Mesna
6
Lenalidomide
6
Ipilimumab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Tablets
×
Lymphoid
×
Clear all
NCT00748189
2019-06-25
COMPLEMENT 1
Novartis
Phase 3
Terminated
447 enrolled
32 charts